Cardiovascular disease in breast cancer patients receiving chemotherapy: epidemiology and risk factors

Clicks: 1
ID: 323305
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #125 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Breast cancer is the most common malignancy among women worldwide, and chemotherapy remains a cornerstone of its treatment. However, chemotherapy can increase the risk of cardiovascular disease (CVD), which is a major cause of morbidity and mortality in cancer survivors. Understanding the prevalence and risk factors for CVD in this population is essential for improving long-term outcomes. This study aimed to evaluate the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and to identify factors associated with increased risk. Methods We conducted a retrospective cohort study using administrative data from a Slovak health insurance company covering 1.77 million insurees (2024). We included women with breast cancer (ICD-10: C50*) who initiated chemotherapy (ATC groups L01 or L02) between 2013 and 2024. Baseline CVD status was assessed using administrative records from the two years prior to chemotherapy initiation. New-onset CVD was ascertained from the date of treatment initiation and followed for a mean of 3.8 years (SD 3.4). To identify factors associated with incident CVD, we applied multivariate Cox proportional hazards regression in the subset of patients without prior CVD. Results 10,171 women with mean age of 60.2 (SD 12.6) started chemotherapy treatment for breast cancer between years 2013 and 2024. 62.8% of them had no CVD present at the start of treatment (except for hypertension), with mean age of 55.8 (SD 11.4). Share of patients with CVD increased to 49.1% at 1 year and 63.3% at 5 years after treatment initiation. In CVD-naive patients, ischaemic heart disease was the most common CVD, with 13.0% of patients developing it within 5 years, followed by arrythmia (10.5%), atherosclerosis (8.3%), embolism and thrombosis (7.8%) and heart failure (4.7%). In patients with established CVD, the prevalence of individual diagnoses shows around two-fold increase within 5 years (Table 1). Model showed that higher age (40–64 years: HR = 1.38, ≥65 years: HR = 2.13), presence of hypertension (HR = 1.69), diabetes (HR = 1.18), chronic kidney failure (HR = 1.60) and longer chemotherapy episodes (1–4 years: HR = 1.12, ≥4 years: HR = 1.18) were significantly associated with higher CVD risk, while initial chemotherapy of L02 class was associated with lower risk (HR = 0.75). Conclusion Cardiovascular disease represents a substantial and increasing burden among women undergoing chemotherapy for breast cancer. A large proportion of initially CVD-naive patients developed cardiovascular conditions over follow-up. Among incident diagnoses, ischaemic heart disease had the highest 5-year cumulative incidence, followed by arrhythmias, thromboembolic events, and atherosclerotic disease. Together with the approximately two-fold higher prevalence observed in patients with preexisting CVD, this study highlights the need for sustained cardiovascular surveillance in breast cancer survivors.Table 1Prevalence of selected CVD
Reference Key
openalex_W7172340328 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors V Dvorovy, L Kovacova, M Selvek, B Saal, R Muzik
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.056
URL
https://doi.org/10.1093/eurheartjsupp/suag097.056
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.